These data confirmed an important contribution of group I PAK signaling to Rac1-driven melanoma cell resistance to BRAF inhibitors; however, these findings also have important implications for efforts to develop PAK1-selective inhibitors that circumvent the cardiotoxic effects of PAK2 co-inhibition [26] (See Discussion). The gene discussed is PAK2; the disease is melanoma.